Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.41 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.36 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | HTR6 | P50406 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.35 |
| ▸ | PTGIR | P43119 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL5094982 | 0.89 | TACR1 (0.43) | TACR1KDM4EHTR6PTGDR2PTGDR | |
| SCHEMBL5094690 | 0.87 | HTR6 (0.44) | TACR1HTR6PTGDR2PTGDRPTGIR | |
| Hydrochloric Acid SCHEMBL5094866 | 0.86 | HTR6 (0.43) | TACR1HTR6PTGDR2PTGDRPTGIR | |
| Maleic Acid SCHEMBL5094863 | 0.86 | TACR1 (0.42) | TACR1HTR6PTGDR2PTGDRPTGIR | |
| Citric Acid SCHEMBL5101057 | 0.82 | PTGDR2 (0.37) | TACR1LMNAKDM4EMEN1CYP1A2 | |
| SCHEMBL5095599 | 0.76 | TACR1 (0.41) | TACR1HTR6CYP2D6PTGDR2PTGDR | |
| SCHEMBL5094719 | 0.76 | TACR1 (0.52) | TACR1LMNAKDM4EHTR6MEN1 | |
| SCHEMBL5101411 | 0.75 | RXRA (0.45) | TACR1HTR6SMN1; SMN2 | |
| SCHEMBL5089907 | 0.75 | HTR6 (0.44) | TACR1LMNAHTR6MEN1CYP1A2 | |
| SCHEMBL5095637 | 0.74 | HTR6 (0.57) | TACR1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317035-B2 | Tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2008-01-08 | — | — | US | claimed |
| EP-1517909-B1 | NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2006-10-25 | — | — | EP | claimed |
| EP-1517909-A2 | NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Suven Life Sciences Limited (IN) | 2005-03-30 | — | — | EP | claimed |
| WO-2004000205-A2 | NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LIMITED (IN) | 2003-12-31 | — | — | WO | claimed |
| US-7317035-B2 | Tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2008-01-08 | — | — | US | disclosed |
| EP-1517909-B1 | NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2006-10-25 | — | — | EP | disclosed |
| US-20050250834-A1 | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-11-10 | — | — | US | disclosed |
| EP-1517909-A2 | NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Suven Life Sciences Limited (IN) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000205-A2 | NOVEL TETRACYCLIC ARYLCARBONYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LIMITED (IN) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250834-A1 | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them | TPH1, HTR1A, HTR5A | TACR1 74/4885MEN1 3355/4885ESR1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.